Standard Treatments and Managing Risks
At a Glance
Anti-GBM disease is treated urgently, often with plasma exchange, high-dose steroids, and cyclophosphamide to remove harmful antibodies, reduce inflammation, and prevent new antibodies. Treatment is individualized, with close monitoring for infection, blood-count changes, and organ-specific risks.
The goal of treating Anti-GBM disease is to stop the immune system’s attack before it causes irreversible damage to your kidneys and lungs. Because the disease is so aggressive, doctors often utilize an intensive “Triple Therapy” protocol [1][2]. However, this regimen is not a rigid, universal guarantee; your specialists will carefully tailor the use and duration of these treatments based on your kidney biopsy findings, whether you have lung bleeding, your age, and your individual risks for severe side effects.
The Triple Therapy Approach
If your team determines that aggressive treatment is appropriate, they will likely use three different methods simultaneously:
- Plasmapheresis (Plasma Exchange): This machine-based process physically filters your blood to remove the existing anti-GBM antibodies [3]. A typical course may involve daily or every-other-day sessions, and the total number of sessions depends heavily on how quickly your antibody levels fall and your symptoms improve [3][4].
- High-Dose Corticosteroids: You will likely receive “pulses” of intravenous steroids (like methylprednisolone) followed by oral prednisone [1][5]. These act like a powerful “fire extinguisher” to quickly suppress acute inflammation.
- Cyclophosphamide: While steroids treat the inflammation, cyclophosphamide is a potent immunosuppressant that slows down the immune cells making new anti-GBM antibodies [1][6].
The Role of Rituximab
Rituximab is an alternative powerful medication that specifically depletes CD20-positive B cells (the cells that eventually mature into antibody-producing cells). It is not definitively proven to be superior to cyclophosphamide as a first-line treatment for saving kidney function. However, your doctor might recommend it for specific cases, such as if you cannot tolerate cyclophosphamide, if your disease is particularly refractory (stubborn), or as part of a highly individualized plan [6][7][8]. Patients receiving rituximab must be monitored for infusion reactions and screened for conditions like Hepatitis B.
Understanding the Risks and Managing Side Effects
Because these treatments forcefully suppress your immune system to save your organs, they carry serious risks. Your medical team will monitor you constantly, but you must also know what to watch for.
1. Severe Infection Risk
Because your immune system is severely weakened, you are highly vulnerable to common infections (like the flu or COVID-19) and rare opportunistic infections (like Pneumocystis pneumonia) [3][9].
- What to watch for: Any fever, new cough, or sudden fatigue must be reported to your team immediately [3].
- Prevention: Your team may prescribe preventative (“prophylactic”) antibiotics to protect you. You should avoid live vaccines while significantly immunosuppressed, but discuss the timing of safe, non-live vaccines with your doctors [3][10].
2. Blood Count Changes (Cytopenias)
Cyclophosphamide can cause your bone marrow to produce fewer blood cells. This can lead to leukopenia (low white blood cells, increasing infection risk), anemia (low red blood cells, causing extreme fatigue), or thrombocytopenia (low platelets, increasing bleeding risk) [11][12]. Your doctors will perform frequent blood tests to monitor these levels.
3. Steroid Side Effects
High-dose corticosteroids are necessary but can cause significant side effects, including severe insomnia, mood swings or psychiatric changes, high blood pressure, high blood sugar (hyperglycemia), stomach issues, and bone loss [5]. Never stop taking prednisone abruptly without medical advice, as this can cause a life-threatening adrenal crisis.
4. Fertility and Bladder Health (Cyclophosphamide)
- Infertility: Cyclophosphamide carries a risk of permanent infertility depending on the dose, route, your age, and your sex. You should have an urgent discussion with your nephrologist and a fertility specialist (regarding sperm banking, egg preservation, or ovarian protection) before treatment if feasible, without delaying life-saving emergency care [1].
- Bladder Irritation: A byproduct of cyclophosphamide can irritate the bladder, potentially causing hemorrhagic cystitis (bleeding). Your team may use a protective medication called mesna. Crucially, you must follow your nephrologist’s exact instructions regarding fluid intake. While extra fluids are sometimes used to flush the bladder, drinking too much fluid can be extremely dangerous if you have kidney failure, are on dialysis, or have lung fluid (pulmonary hemorrhage). Do not increase your fluid intake without explicit permission from your kidney team [1]. Report any blood in your urine or painful urination immediately.
5. Plasma Exchange Complications
During plasma exchange, you may experience reactions to the replacement fluids, tingling in your fingers or lips (due to low calcium), changes in blood pressure, or bleeding/infection at the central catheter site [13][14]. Your nurses will monitor you throughout each session to manage these symptoms safely.
While these risks are profound, they are carefully weighed against the life-threatening nature of the disease itself. Open, daily communication with your care team ensures your treatment is as safe and effective as possible [9][3].
Common questions in this guide
What is triple therapy for anti-GBM disease?
How long will I need plasma exchange for anti-GBM disease?
When is rituximab used instead of cyclophosphamide?
What infection symptoms should I report during anti-GBM treatment?
Can cyclophosphamide affect fertility?
How much fluid should I drink with cyclophosphamide?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.What is our specific plan for monitoring my white blood cell count to ensure my immune system hasn't dropped to a dangerous level?
- 2.Will I be given medications (like sulfamethoxazole/trimethoprim) to prevent specific 'opportunistic' infections while on this intensive treatment?
- 3.Given the risks to fertility with cyclophosphamide, can we quickly consult with a fertility specialist without dangerously delaying my urgent treatment?
- 4.How will you decide when it is safe to stop the plasma exchange sessions based on my antibody levels and symptoms?
- 5.What is my individualized fluid and hydration plan while taking cyclophosphamide, considering my kidney function and risk of fluid overload?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
References
References (14)
- 1
Anti-glomerular basement membrane disease-treatment standard.
McAdoo SP, Pusey CD
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2025; (41(1)):42-54 doi:10.1093/ndt/gfaf190.
PMID: 40973182 - 2
Antiglomerular Basement Membrane Disease.
McAdoo SP, Pusey CD
Seminars in respiratory and critical care medicine 2018; (39(4)):494-503 doi:10.1055/s-0038-1669413.
PMID: 30404116 - 3
Immunity in the balance: Fatal disseminated adenovirus infection in a patient undergoing plasma exchange and immunosuppressive chemotherapy for anti-glomerular basement membrane disease.
Jacobs JW, Figueroa Villalba CA, Stendahl K, et al.
Journal of clinical apheresis 2023; (38(6)):770-777 doi:10.1002/jca.22088.
PMID: 37698143 - 4
Therapeutic plasma exchange for anti-glomerular basement membrane disease with dialysis-dependent kidney failure without diffuse alveolar hemorrhage.
Watanabe H, Yamana H, Okada A, et al.
Journal of nephrology 2023; (36(8)):2317-2325 doi:10.1007/s40620-023-01695-9.
PMID: 37354278 - 5
Antiglomerular Basement Membrane (Anti-GBM) Glomerulonephritis in the Context of Genitourinary Tuberculosis: A Case Report.
Tan SM, Shanizza QIBA, Balingi D, et al.
Kidney medicine 2026; (8(5)):101338 doi:10.1016/j.xkme.2026.101338.
PMID: 42040508 - 6
The Immunobiological Agents for Treatment of Antiglomerular Basement Membrane Disease.
Yamashita M, Takayasu M, Maruyama H, Hirayama K
Medicina (Kaunas, Lithuania) 2023; (59(11)) doi:10.3390/medicina59112014.
PMID: 38004064 - 7
Rituximab is associated with accelerated dialysis independence in anti-glomerular basement membrane disease: a retrospective cohort analysis of renal survival.
Wang Y, Zhai Z, Wang L, et al.
Frontiers in immunology 2026; (17()):1835889 doi:10.3389/fimmu.2026.1835889.
PMID: 42199438 - 8
Efficacy and Safety of Rituximab in Antiglomerular Basement Membrane Disease.
Ivković V, Bajema I, Bruchfeld A, et al.
Kidney international reports 2025; (10(3)):743-752 doi:10.1016/j.ekir.2024.12.026.
PMID: 40225363 - 9
A case of anti-glomerular basement membrane disease complicated by severe cytomegalovirus enteritis in a patient who survived after a prolonged ICU stay.
Terunuma Y, Moniwa N, Maeda T, et al.
CEN case reports 2025; (14(4)):653-658 doi:10.1007/s13730-025-00998-z.
PMID: 40382750 - 10
Case Report: Elderly anti-GBM antibody disease with diffuse non-hereditary glomerular basement membrane thinning of uncertain etiology.
Yu P, Yang W, Weiwei Z, et al.
Frontiers in medicine 2026; (13()):1883699 doi:10.3389/fmed.2026.1883699.
PMID: 42602475 - 11
Etanercept-Induced Anti-Glomerular Basement Membrane Disease.
Al-Chalabi S, Wu HHL, Chinnadurai R, Ponnusamy A
Case reports in nephrology and dialysis 2021; (11(3)):292-300 doi:10.1159/000518984.
PMID: 34722648 - 12
Acquired aplastic anemia complicated with anti-glomerular basement membrane disease successfully treated with immunosuppressive therapy: a case report.
Matsui K, Kamata W, Mochida Y, et al.
BMC nephrology 2022; (23(1)):136 doi:10.1186/s12882-022-02772-0.
PMID: 35392836 - 13
Double-filtration plasmapheresis versus therapeutic plasma exchange in the treatment of anti-glomerular basement membrane nephritis: A cohort study.
Liu C, Wei W, Huang Y, et al.
The American journal of the medical sciences 2025; (370(4)):338-346 doi:10.1016/j.amjms.2025.07.007.
PMID: 40675370 - 14
Multimodal Management of Anti-GBM Disease Complicated by Secondary Complement-Mediated Thrombotic Microangiopathy in a Patient Intolerant to Plasma Exchange: A Case Report.
Yang X, Guo P, Ma L, et al.
Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy 2026; doi:10.1002/1744-9987.70172.
PMID: 42259390
This page explains Anti-GBM disease treatments and treatment risks for informational purposes only; it does not replace medical advice. Follow your nephrology team's individualized instructions, especially about medicines, infection warnings, and fluid intake.
Get notified when new evidence is published on anti-basement membrane glomerulonephritis.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.